The US market for Hemostats and Sealants began the journey back to normalcy, slipping -0.2% YoY in Q320, as elective surgeries began to be performed again. Hemostats led the charge with Sealants not far behind.
As the US healthcare system begins to manage COVID-19 and elective procedures return toward pre-COVID-19 levels, the US Hemostats and Sealants market rebounded with a drop of only -0.2% YoY in Q320 according to SmartTRAK Financial Dashboard. Most manufacturers still experienced declines in Q320, but far narrower than the losses of Q220. Ethicon* managed a +4.5% gain in Q320 while the other manufacturers essentially treaded water with respect to Q319.
Among the many topics covered in the comprehensive Q320 US Hemostats and Sealants Market Recap* are:
- Complete US Hemostats & Sealants Market Overview
- Companies' Revenue and Market Shares
- Biosurgery Market Regains Its Footing
- Absorbable Hemostats Lead The Charge Back
- Fibrin Sealants Lead The Recovery
- Q320 Regulatory Events and Clinical Trials
As before the COVID-19 downturn, Ethicon continued to lead the overall US Hemostat and Sealants market in Q320 and managed to post a gain of +4.3% YoY to $
MM* in revenue and 42.7% market share, in large part due to its widespread presence in hospitals where it could take advantage faster of the recovery in procedures. A recovering Baxter nonetheless fell behind Ethicon, while Becton Dickinson* (BD) in third place gained slightly on Baxter, posting revenue of ...
Read the entire Q320 US Hemostats and Sealants Market Recap including news, data, charts, company revenues, shares and analysis*
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution that networks an entire organization with real-time market data and analysis. Used by the 15 top Advanced Wound Care companies and 8 of the 10 top Orthopedic companies, SmartTRAK transforms the delivery of healthcare business information into a cost-effective solution for life science corporations to increase proficiency, improve productivity and reduce cost.
